Lymphoma is the most common type of blood cancer and it is caused by abnormal growth and reproduction of white blood cells called lymphocytes. Patients are more likely to be older than age 60; men and women equally. It usually manifests first with swollen but painless lymph nodes. Prognosis can be encouraging for the more common non-Hodgkin’s lymphoma.

Where To Find Information On Lymphoma Clinical Trials

There are two main sources for information about lymphoma clinical trials, according to the Lymphoma Research Foundation, the largest non-profit organization in the country devoted exclusively to funding innovative lymphoma research and providing public information.

The website at National Institutes of Health (NIH), sponsored by the National Library of Medicine and the NIH, and includes hundreds of lymphoma trials. Another website at the National Cancer Institute (NCI) also lists lymphoma clinical trials.

Additionally, operated by the U.S.  government, lists all clinical trials worldwide for lymphoma and other diseases. While the lists are comprehensive, the search function and information presented has been reported to be less user-friendly than sites managed by advocacy groups.

To participate in a lymphoma clinical trial, patients must fulfill requirements regarding age, sub-type of lymphoma and stage, previous types of treatments, timing, response, and overall health condition.

Other characteristics like geographic area may also be required. Hundreds of clinical trials are currently taking place in hospitals, cancer centers and laboratories nationwide. Prior to applying or accepting participate in a study, it is important for patients to carefully read the clinical trial’s fact sheet and all information provided.

Current Notable Lymphoma Clinical Trials:

For lymphoma clinical trials currently recruiting patients, log on

RSS lymphoma | Recruiting Studies | First posted in the last 14 days

  • Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   LeukemiaInterventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: FilgrastimSponsor:   Memorial Sloan Kettering Cancer CenterRecruiting
  • PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Haematopoietic Stem Cell Transplant, Autologous;   Haematopoietic Stem Cell Transplant, Allogeneic;   Febrile NeutropeniaInterventions:   Diagnostic Test: FDG-PET/CT;   Diagnostic Test: Conventional CTSponsors:   Peter MacCallum Cancer Centre, Australia;   Melbourne Health;   Westmead Hospital;   Victorian Infectious Diseases Reference LaboratoryRecruiting
  • Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
    Conditions:   CD19-chimeric Antigen Receptor T Cells;   Relapsed and/or Refractory Acute Lymphoblastic Leukemia;   the Haploidentical Hematopoietic Stem Cell TransplantationIntervention:   Procedure: the new model of haplo-HSCT for r/r B-ALLSponsor:   First Affiliated Hospital of Harbin Medical UniversityRecruiting
  • Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
    Conditions:   Advanced or Metastatic Solid Tumours;   Breast Cancer;   Colorectal Cancer;   Gastric Cancer;   Cholangiocellular Carcinoma;   Ovarian Cancer;   Cervical Cancer;   Prostate Cancer;   Melanoma;   Sarcoma;   NSCLC;   Desmoid Tumour;   Adenoid Cystic Carcinoma;   Glioblastoma Multiforme;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple MyelomaIntervention:   Drug: CB-103Sponsor:   Cellestia Biotech AGRecruiting
  • Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
    Condition:   Adult Acute Lymphoblastic LeukemiaInterventions:   Drug: PLD;   Drug: DNRSponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Recruiting

More Lymphoma Insights

Leave a Comment

Your email address will not be published. Required fields are marked *